Novel approaches to the immunotherapy of B-cell malignancies: An update.
Novel approaches to the immunotherapy of B-cell malignancies: An update.
复制标题
B 细胞恶性肿瘤免疫治疗的新方法：更新。
DOI：
10.1007/s11899-006-0007-6
复制
发表时间：
2006
影响因子：
2.9
通讯作者：
Brentjens,RenierJ
中科院分区：
文献类型：
--
作者：
Brentjens,RenierJ
癌症的免疫治疗包括主动和过继或被动免疫形式，以靶向和根除宿主中的恶性B细胞。对宿主免疫系统的免疫学和肿瘤细胞逃避的理解的进展，加上操纵免疫效应物和肿瘤的改进技术，已经导致了广泛的B细胞恶性肿瘤的新疗法。因此，研究人员已经提出并测试了许多能够引发对肿瘤抗原的免疫应答的疫苗策略。此外，B细胞靶向抗体疗法的新方法有望推进这一治疗路线，有效的基因转移技术使研究人员能够操纵免疫效应细胞以增强抗肿瘤活性。值得注意的是，越来越多的这些新的基于免疫的疗法正在应用于临床环境。这些临床试验的结果，结合进一步的临床前研究，是否最终会转化为B细胞恶性肿瘤患者的生存率提高，还有待观察。
Immunotherapy of cancer includes both active and adoptive, or passive, forms of immunization to target and eradicate malignant B cells in the host. Advances in the understanding of immunology and tumor-cell evasion of the host immune system, coupled with improved technologies to manipulate immune effectors and tumors, have led to a wide array of novel therapies for B-cell malignancies. As a result, investigators have proposed and tested numerous vaccine strategies able to elicit immune responses to tumor antigens. Furthermore, novel approaches to B-cell-targeted antibody therapies hold promise in advancing this line of treatment, and efficient gene transfer technologies have enabled investigators to manipulate immune effector cells to enhance antitumor activity. Significantly, an increasing number of these novel immune-based therapies are being applied to the clinical setting. Whether findings from these clinical trials, in combination with further preclinical studies, will ultimately translate into improved survival of patients with B-cell malignancies remains to be seen.